Saturday 17 October 2026
Export SCNX’s income statement to Excel — free account
Scienture Holdings, Inc.
SCNX Healthcare Pharmaceutical Retailers
Scienture Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $431,600.00, up 216.0% from fiscal 2024. In the quarter to June 2026, revenue grew 3,235.9%, EPS grew 85.4%, free cash flow fell 54.0% and total debt rose 831.4%, each against the same quarter a year earlier.
3.36
0.02
−0.59%
Follow SCNX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | 5 | 4 | 4 | 2 | 4 | 2 | 4 | 5 |
P/E ratio |
0.00 | 1,244.93 | 26,785.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.15 | 0.00 |
P/S ratio |
146.25 | 122.73 | 63.17 | 131.63 | 59.55 | 48.57 | 6.10 | 74.93 | 2,055.03 | 403.62 |
Altman Z-Score |
105.17 | 220.85 | 101.84 | 410.34 | 549.80 | 139.83 | 7.92 | (0.64) | 10.88 | 5.42 |
Altman Z″-Score (non-manufacturers) |
(124.35) | (38.05) | (9.71) | 2.14 | 8.44 | (9.45) | (22.60) | (15.57) | 0.96 | (0.88) |
P/FCF ratio |
0.00 | 2,095.17 | 885.35 | 21,996.91 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(1,600.42) | 6,749.37 | 5,749.52 | (5,354.83) | (1,425.08) | (1,125.59) | 52.46 | (100.27) | (175.45) | (37.81) |
Beneish M-Score |
(13.36) | (1.24) | (2.47) | (1.72) | (1.19) | (4.34) | (3.87) | 14.21 | 19.51 | (3.19) |
P/B ratio |
0.00 | 0.00 | 286.56 | 236.43 | 117.48 | 127.39 | 182.25 | 188.39 | 6.46 | 2.79 |
Price to Tangible BV |
0.00 | 0.00 | 2,039.22 | 286.70 | 128.21 | 157.77 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
146.28 | 122.82 | 63.10 | 131.29 | 59.24 | 48.38 | 6.06 | 75.10 | 2,057.92 | 394.23 |
EV/EBITDA |
0.00 | 744.16 | 0.00 | 4,435.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(721.02) | 2,096.82 | 884.31 | 6,885.07 | (457.99) | (186.43) | (39.69) | (46.03) | (35.83) | (14.28) |
EV/FCF |
(721.02) | 2,096.82 | 884.31 | 21,939.40 | (450.36) | (183.81) | (39.70) | (48.63) | (30.38) | (11.99) |
Quick Ratio |
0.21 | 0.96 | 1.51 | 7.03 | 9.28 | 4.43 | 0.80 | 0.11 | 0.56 | 2.70 |
Current Ratio |
0.23 | 1.16 | 1.70 | 7.30 | 10.95 | 4.72 | 0.98 | 0.24 | 0.80 | 2.89 |
Net Debt/EBITDA |
(0.86) | 1.00 | 0.29 | (11.63) | 2.20 | 0.36 | 0.15 | (0.01) | (0.05) | 0.17 |
Debt/Assets |
231.80% | 107.92% | 37.89% | 5.61% | 6.41% | 21.65% | 18.78% | 0.20% | 0.98% | 0.00% |
Debt/Equity |
(0.68) | (2.14) | 1.00 | 0.08 | 0.07 | 0.33 | 2.03 | 0.05 | 0.01 | 0.00 |
Asset Turnover |
2.10 | 6.14 | 2.69 | 1.91 | 2.23 | 1.27 | 2.16 | 0.17 | 0.00 | 0.00 |
Operating CF/Net income |
0.18 | 0.59 | 30.38 | (0.50) | 0.87 | 0.48 | 0.45 | 0.12 | (1.57) | 0.32 |
Capex/Depreciation |
0.00 | 0.00 | (75.00) | (0.87) | (0.37) | (0.16) | 0.00 | 0.00 | (0.01) | 0.00 |
Interest Coverage |
(6.65) | 2.52 | (1.52) | 2.35 | (85.26) | (224.25) | (8.67) | (3.85) | (11.01) | (10.43) |
| 626.51% | (39.59%) | 3.38% | (11.41%) | (39.57%) | (85.40%) | (168.83%) | (4,031.09%) | 22.77% | (55.65%) | |
| (233.43%) | 60.55% | 0.63% | (7.29%) | (33.01%) | (68.33%) | (73.28%) | (219.71%) | 15.45% | (43.92%) | |
ROIC |
0.00% | 144.75% | (6.68%) | 4.95% | (46.25%) | (174.44%) | 0.00% | (484.54%) | (11.52%) | (41.95%) |
Return on Tangible Assets |
242.65% | 352.01% | 1.45% | (8.23%) | (29.69%) | (149.87%) | (30,192.17%) | 202.87% | (572.37%) | (798.85%) |
Average Days of Receivables |
43.99 | 39.78 | 41.30 | 38.88 | 40.35 | 36.13 | 22.43 | 327.77 | 11,088.68 | 618.45 |
Research and Development Expense of Revenue |
11.56% | 12.80% | 24.79% | 8.70% | 3.87% | 0.00% | 0.00% | 0.00% | 1,637.41% | 453.27% |
Selling, General and Administrative Expense of Revenue |
140.58% | 86.52% | 90.57% | 58.86% | 43.73% | 58.07% | 51.42% | 143.95% | 6,433.82% | 2,327.29% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.33 | 0.13 | 0.00 | 0.00 | 0.12 | 0.72 | 0.93 | 0.84 |
Share Based Compensation of Revenue |
5.95% | 9.56% | 4.43% | 3.79% | 10.88% | 3.94% | 3.25% | 21.08% | 3,384.99% | 1,477.99% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | (0.02) | (0.09) | (0.04) | (0.03) |
Graham Number |
24.95 | 0.00 | 1.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.68 | 0.00 |
Earnings Yield |
(0.82%) | 0.08% | 0.00% | (0.03%) | (0.24%) | (1.10%) | (5.56%) | (17.49%) | 1.78% | (21.65%) |
Free Cash Flow Yield |
(0.14%) | 0.05% | 0.11% | 0.00% | (0.22%) | (0.54%) | (2.50%) | (2.06%) | (3.30%) | (8.15%) |
Revenue per Share |
7.08 | 8.25 | 10.69 | 18.80 | 33.31 | 18.22 | 18.15 | 1.79 | 0.04 | 0.03 |
Operating CF per Share |
(1.44) | 0.48 | 0.76 | 0.36 | (4.31) | (4.73) | (2.77) | (2.91) | (4.23) | (0.87) |
Capex per Share |
0.00 | 0.00 | (0.04) | (0.21) | (0.07) | (0.04) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.44) | 0.48 | 0.72 | 0.15 | (4.38) | (4.77) | (2.77) | (2.91) | (4.23) | (0.87) |
Cash per Share |
0.04 | 0.52 | 2.43 | 7.26 | 11.52 | 5.75 | 1.94 | 0.00 | 0.09 | 0.43 |
Shareholders Equity per Share |
(3.27) | (0.88) | 2.36 | 10.47 | 16.89 | 6.95 | 0.61 | 0.71 | 23.43 | 4.57 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(3.27) | (0.88) | 2.36 | 10.47 | 16.89 | 6.95 | 0.61 | 0.71 | 23.43 | 4.57 |
Free Cash Flow |
(0.50) | 0.17 | 0.26 | 0.06 | (2.25) | (2.59) | (1.56) | (2.23) | (14.28) | (13.38) |
Working Capital |
(1.14) | 0.08 | 0.61 | 3.28 | 8.38 | 3.45 | (0.05) | (8.80) | (1.60) | 5.18 |
Capital Expenditures |
— | — | (0.01) | (0.08) | (0.04) | (0.02) | 0.00 | — | (0.01) | — |
Net Current Asset Value |
(1.15) | (0.32) | 0.08 | 2.37 | 8.11 | 2.38 | (1.27) | (9.24) | (19.48) | (6.14) |
EV/EBIT |
0.00 | 911.22 | 0.00 | 7,791.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 |
Price to Operating Income |
0.00 | 910.51 | 0.00 | 7,812.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.01 | 0.54 | 0.63 | 1.41 | 2.99 | 139.97 | 55.19 | 235.67 |
Cash ROIC |
143.04% | 31.89% | 10.10% | 0.81% | (14.79%) | (31.80%) | (73.27%) | (391.97%) | (17.76%) | (17.43%) |
Accounts Receivable Turnover |
7.59 | 9.48 | 10.18 | 12.13 | 12.76 | 6.89 | 12.74 | 1.47 | 0.05 | 0.18 |
Accounts Payable Turnover |
0.07 | 0.00 | 1.77 | 6.98 | 38.60 | 14.02 | 9.41 | 1.32 | 0.06 | 0.05 |
Inventory Turnover |
0.00 | — | 7.10 | 37.51 | 17.37 | 7.83 | 77.68 | 39.54 | 0.00 | 0.93 |
Average Days of Payables |
5,270.24 | 0.00 | 325.57 | 47.60 | 8.21 | 33.85 | 40.74 | 406.14 | 8,101.27 | 5,262.78 |
Days of Inventory on Hand |
0.00 | — | 65.03 | 8.08 | 40.22 | 4.00 | 5.05 | 0.28 | 0.00 | 778.13 |
Average Receivables |
0.33 | 0.31 | 0.38 | 0.61 | 1.34 | 1.44 | 0.80 | 0.93 | 2.69 | 2.44 |
Average Payables |
0.23 | 0.17 | 0.25 | 0.37 | 0.30 | 0.37 | 0.50 | 1.00 | 2.18 | 2.17 |
Average Inventory |
— | — | 0.06 | 0.07 | 0.66 | 0.66 | 0.06 | 0.03 | — | 0.11 |
Average Assets |
1.18 | 0.48 | 1.42 | 3.90 | 7.68 | 7.78 | 4.74 | 8.12 | 58.69 | 94.52 |
Average Common Equity |
(0.44) | (0.73) | 0.27 | 2.49 | 6.41 | 6.22 | 2.06 | 0.44 | 39.81 | 74.60 |
Columns are period end dates